{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:09:02Z","timestamp":1782310142135,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","gastro.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.gtc.2014.05.012","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T09:30:44Z","timestamp":1403688644000},"page":"581-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases"],"prefix":"10.1016","volume":"43","author":[{"given":"Masayuki","family":"Saruta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos A.","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2014.05.012_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.gtc.2014.05.012_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11894-009-0072-9","article-title":"Insights into IBD pathogenesis","volume":"11","author":"Shih","year":"2009","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.gtc.2014.05.012_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","article-title":"The treatment-naive microbiome in new-onset Crohn's disease","volume":"15","author":"Gevers","year":"2014","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.gtc.2014.05.012_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-014-1543-4","article-title":"The histopathological approach to inflammatory bowel disease: a practice guide","volume":"464","author":"Langner","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.gtc.2014.05.012_bib5","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib6","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2011.02.014","article-title":"Future therapeutic approaches for inflammatory bowel diseases","volume":"140","author":"Plevy","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2014.05.012_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12407","article-title":"Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease","volume":"38","author":"Khanna","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2014.05.012_bib9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/BF01645144","article-title":"Role of neutrophil-derived oxidants in the pathogenesis of intestinal inflammation","volume":"69","author":"Yamada","year":"1991","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.gtc.2014.05.012_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","article-title":"T-cell function and migration. Two sides of the same coin","volume":"343","author":"von Andrian","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.med.45.1.361","article-title":"Endothelial-leukocyte adhesion molecules in human disease","volume":"45","author":"Bevilacqua","year":"1994","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2014.05.012_bib13","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/gutjnl-2011-300904","article-title":"New therapies for inflammatory bowel disease: from the bench to the bedside","volume":"61","author":"Danese","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2014.05.012_bib14","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1572-0241.2005.41089.x","article-title":"Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment","volume":"100","author":"Sawada","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2014.05.012_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s004410100417","article-title":"Function and interactions of integrins","volume":"305","author":"van der Flier","year":"2001","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.gtc.2014.05.012_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00441-009-0834-6","article-title":"Integrins","volume":"339","author":"Barczyk","year":"2010","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.gtc.2014.05.012_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: bidirectional, allosteric signaling machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.gtc.2014.05.012_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(87)90104-8","article-title":"Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)","volume":"51","author":"Marlin","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.gtc.2014.05.012_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0016-5085(98)70328-2","article-title":"Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease","volume":"114","author":"Panes","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","article-title":"VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site","volume":"60","author":"Elices","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.gtc.2014.05.012_bib21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.4049\/jimmunol.159.3.1497","article-title":"Structure-function analysis of the integrin beta 7 subunit: identification of domains involved in adhesion to MAdCAM-1","volume":"159","author":"Tidswell","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.012_bib22","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.gtc.2014.05.012_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02063969","article-title":"Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis","volume":"40","author":"Pooley","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2014.05.012_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0016-5085(92)90015-Q","article-title":"Expression of vascular adhesion molecules in inflammatory bowel disease","volume":"103","author":"Koizumi","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib25","first-page":"77","article-title":"In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells","volume":"69","author":"Nakamura","year":"1993","journal-title":"Lab Invest"},{"key":"10.1016\/j.gtc.2014.05.012_bib26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3109\/00365529509101601","article-title":"Adhesion molecule expression on vascular endothelium and nitroblue tetrazolium reducing activity in human colonic mucosa","volume":"30","author":"Oshitani","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2014.05.012_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/23495","article-title":"The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells","volume":"400","author":"Campbell","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.gtc.2014.05.012_bib28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1172\/JCI119633","article-title":"Expression of mucosal homing receptor alpha4beta7 by circulating CD4+ cells with memory for intestinal rotavirus","volume":"100","author":"Rott","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.gtc.2014.05.012_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1440-1827.2002.01365.x","article-title":"Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease","volume":"52","author":"Arihiro","year":"2002","journal-title":"Pathol Int"},{"key":"10.1016\/j.gtc.2014.05.012_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.110.169714","article-title":"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease","volume":"335","author":"Walters","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.gtc.2014.05.012_bib32","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A\u00a0randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib35","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2036.2002.01205.x","article-title":"A\u00a0pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin","volume":"16","author":"Gordon","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2014.05.012_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","article-title":"Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity","volume":"204","author":"Gorelik","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.gtc.2014.05.012_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib39","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.crohns.2013.03.014","article-title":"Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice","volume":"7","author":"Sugiura","year":"2013","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.gtc.2014.05.012_bib40","doi-asserted-by":"crossref","first-page":"A181","DOI":"10.1016\/S0016-5085(09)60816-7","article-title":"Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease-A randomized, double-blind, placebo-controlled trial","volume":"136","author":"Takazoe","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2014.05.012_bib41","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S0016-5085(14)60293-6","article-title":"AJM300, an oral alpha4 integrin antagonist for active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled phase 2A study","volume":"146","author":"Watanabe","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib42","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib43","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2014.05.012_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.012_bib45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2014.05.012_bib46","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1873-9946(13)60012-4","article-title":"Vedolizumab induction therapy for patients with Crohn's disease and prior anti-tumour necrosis factor antagonist failure: a randomized, placebo-controlled, double-blind, multicentre trial","volume":"7","author":"Sands","year":"2013","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.gtc.2014.05.012_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bph.12134","article-title":"Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells","volume":"169","author":"Pan","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.gtc.2014.05.012_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1476-5381.2009.00137.x","article-title":"Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody","volume":"157","author":"Pullen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.gtc.2014.05.012_bib49","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2014.05.012_bib50","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1873-9946(14)60008-8","article-title":"Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: results from the TOSCA study","volume":"8","author":"D'Haens","year":"2014","journal-title":"J\u00a0Crohn's Colitis"},{"key":"10.1016\/j.gtc.2014.05.012_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0092-8674(89)90981-1","article-title":"Identification of a murine Peyer's patch\u2013specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha","volume":"56","author":"Holzmann","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.gtc.2014.05.012_bib52","doi-asserted-by":"crossref","first-page":"8254","DOI":"10.1073\/pnas.89.17.8254","article-title":"Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing","volume":"89","author":"Hu","year":"1992","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.gtc.2014.05.012_bib53","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.4049\/jimmunol.150.8.3459","article-title":"Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells","volume":"150","author":"Cepek","year":"1993","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.012_bib54","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1476-5381.2011.01205.x","article-title":"A\u00a0humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes","volume":"162","author":"Stefanich","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.gtc.2014.05.012_bib55","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib56","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.158.5.2099","article-title":"Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T\u00a0cells","volume":"158","author":"Picarella","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.012_bib57","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A\u00a0randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2014.05.012_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.012_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00054725-200011000-00007","article-title":"The role of chemokines and chemokine receptors in mucosal inflammation","volume":"6","author":"Papadakis","year":"2000","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2014.05.012_bib60","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.4049\/jimmunol.165.9.5069","article-title":"The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system","volume":"165","author":"Papadakis","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.012_bib61","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/gast.2001.27154","article-title":"CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease","volume":"121","author":"Papadakis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib62","doi-asserted-by":"crossref","first-page":"e60094","DOI":"10.1371\/journal.pone.0060094","article-title":"A\u00a0randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease","volume":"8","author":"Keshav","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gtc.2014.05.012_bib63","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0016-5085(98)70418-4","article-title":"A\u00a0placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease","volume":"114","author":"Yacyshyn","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/gut.51.1.30","article-title":"Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease","volume":"51","author":"Yacyshyn","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2014.05.012_bib65","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.2001.24015","article-title":"Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease","volume":"120","author":"Schreiber","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.012_bib66","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/gut.2003.036160","article-title":"A\u00a0randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis","volume":"53","author":"van Deventer","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2014.05.012_bib67","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756283X10373176","article-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","volume":"3","author":"Ghosh","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gtc.2014.05.012_bib68","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.4049\/jimmunol.176.4.2161","article-title":"A\u00a0major lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins","volume":"176","author":"Sung","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.012_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3748\/wjg.v20.i1.64","article-title":"Inflammatory pathways of importance for management of inflammatory bowel disease","volume":"20","author":"Pedersen","year":"2014","journal-title":"World J Gastroenterol"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855314000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855314000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T15:19:06Z","timestamp":1689347946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855314000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0889855314000697"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2014.05.012","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2014.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}